

AD _____

GRANT NUMBER DAMD17-94-J-4029

TITLE: New Approaches to the Labeling of Estrogen Useful for PET

PRINCIPAL INVESTIGATOR: Michael J. Welch, Ph.D.
Stephanie D. Jonson

CONTRACTING ORGANIZATION: Washington University
St. Louis, Missouri 63130-4899

REPORT DATE: July 1997

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 5

19980518 041

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 1997	3. REPORT TYPE AND DATES COVERED Annual (1 Jun 96 - 31 May 97)	
4. TITLE AND SUBTITLE New Approaches to the Labeling of Estrogen Useful for PET			5. FUNDING NUMBERS DAMD17-94-J-4029	
6. AUTHOR(S) Michael J. Welch, Ph.D. Stephanie D. Jonson				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Washington University St. Louis, Missouri 63130-4899			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200) Positron Emission Tomography (PET) allows estrogen receptor-positive breast cancer to be diagnostically imaged using radiolabeled estrogens with the benefit of early detection, monitoring, and staging of breast cancer. In order to better target breast cancer, improved estrogen receptor imaging agents are sought. Three new estrogen receptor ligands were synthesized with a methoxy substituted at the 16 position. These compounds were obtained by utilizing the chemistry of methyl hypofluorite (MeOF). Conditions for reacting methyl hypofluorite and steroids were optimized overcoming solubility and solvent problems resulting in decreased formation of side products. Two of the three estradiol analogs were tested for their affinity to bind the estrogen receptor. The results predict these agents to be poor visualizers of breast tumors. The third estrogen, 16α-methoxyestradiol-17β, is currently being tested and based on its structure is predicted to be the superior imaging agent of the three. Synthesis of this third compound required several modifications leaving it the last to be tested. If the binding affinity of this compound is found to be favorable, carbon-11 radiolabeling studies will be initiated to further evaluate the biological effectiveness.				
14. SUBJECT TERMS Breast Cancer, estrogens, receptor ligands, carbon-11, Positron Emission Tomography			15. NUMBER OF PAGES 26	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

____ Where copyrighted material is quoted, permission has been obtained to use such material.

____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

____ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

____ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

____ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

____ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

____ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Stephanie D. Johnson 6/28/97
PI - Signature Date

Table Of Contents

	<u>Page</u>
A. Front Cover	1
B. SF 298	2
C. Foreword.	3
D. Table of Contents	4
E. Introduction	5
F. Body of Report: Results and Discussion	8
G. Conclusion.	15
H. Comments	16
I. Experimental Section	16
J. Statement of Work Time Line.	22
K. List of Abbreviations	23
L. References	25

New Approaches To The Labeling Of Estrogens Useful For PET

Introduction

Imaging estrogen receptors found in estrogen receptor-positive (ER+) breast cancer is made possible through the combined use of radiolabeled estrogens and Positron Emission Tomography (PET). This specific targeting allows non-invasive disease diagnosis and therapy monitoring. The advantages of diagnosing breast cancer at an early stage has spurred research toward the development of improved imaging agents.

Currently, the clinical radiopharmaceutical for breast cancer imagery is [^{18}F]-16 α -fluoroestradiol-17 β (FES).^{5,12,13} Studies with FES display the ability of radiolabeled estrogens and PET to effectively diagnose breast cancer, however, several characteristics of this agent need improvement. This instigated the search for estrogens with higher binding affinity for the estrogen receptor, slower metabolism, and incorporation of a radionuclide with a shorter half-life than fluorine-18 (half-life = 110 m) to decrease the radiation dose given the patient. Substitution of carbon-11 (half-life = 20.4 m) for fluorine-18 was proposed to decrease the radiation dose given the patient, however, carbon-11 chemistry is limited to a small set of carbon-11 precursors restricting the synthesis of estrogen receptor ligands.¹⁰ Therefore, new synthons capable of incorporating carbon-11 into molecules on a short time scale are sought to access estrogen receptor imaging with carbon-11 radioligands.

Methyl hypofluorite (CH_3OF) is one such new carbon-11 incorporating synthon.¹¹ Since the reported isolation and characterization of methyl hypofluorite (CH_3OF) studies have focused on its reactivity.⁹ Methyl hypofluorite is generated from passing fluorine gas (20% in Ne) through methanol in acetonitrile at -40 °C and is reported as the only source of the novel electrophilic methoxylum ion species " CH_3O^+ ".¹⁷ Various enol ethers were found to react with CH_3OF and rapidly form the corresponding α -methoxy ketone.¹⁷

Previously, compounds of this sort were chemically difficult to obtain requiring multi-step syntheses.^{3,14} Applying the chemistry of methyl hypofluorite to the preparation of novel estrogen receptor ligands provides a means of rapid introduction of a methoxy functionality. This allows the biological evaluation of new estrogen derivatives to give useful structure-activity information about the estrogen receptor-ligand binding interaction.




Figure 1.

The targeted compounds for synthesis with CH_3OF were the 16-methoxy estradiol stereoisomers. Four isomers are possible as the α - and β - orientation can differ at the 16 and 17 positions (Figure 1). It is known that estrogen receptor binding requires a ligand to have the 17 β -OH orientation. Therefore, the two isomers with this orientation, 16 α -methoxy estradiol-17 β and 16 β -methoxy estradiol-17 β were desired over the two isomers with the 17 α - configuration.⁶ Previously, only halogen substitutions at the 16-position of estradiol were accessed. Substitutions of fluorine, bromine, and iodine were previously accomplished at both the 16 α - and 16 β -position and relative binding affinity (RBA)

determinations for the estrogen receptor (ER) revealed a preference for 16 α - over 16 β -substitution (Table 1).⁶ This led to the prediction of 16 α -methoxy estradiol-17 β as the isomer with superior binding affinity for the ER. However, this prediction was contingent on the change from an electron-withdrawing halogen to an electron-donating methoxy not disrupting the receptor-ligand binding interaction.

Table 1. Relative binding affinities (RBA) of estrogen receptor ligands substituted at the 16-position.


Compound	16 α	16 β	RBA (0 °C)
Estradiol (ES)	--	--	100
Estriol	OH	--	20
16 α -FES	F	--	76
16 β -FES	--	F	37
16 α -Chloro Estradiol	Cl	--	100
16 α -Bromo Estradiol	Br	--	129
16 β -Bromo Estradiol	--	Br	5.2
16 α -Iodo Estradiol	I	--	93
16 β -Iodo Estradiol	--	I	81

Combining the chemistry of CH₃OF with steroids required the transfer of reaction conditions derived from simple substrates such as enol acetate of 1-indanone¹⁷ to the more chemically complex steroidal substrates. Reaction conditions were optimized for the steroid system to minimize solubility problems and side product formation. The methoxy substituent was introduced into the estrogen by reacting the 17-trimethylsilyl enol ether-3-trifloxy (or benzyloxy) estrone with methyl hypofluorite. Deprotection and reduction conditions were varied to yield the various methoxy estradiol stereoisomers. HPLC purification was required to separate the isomers which were characterized by ¹H NMR and HMQC, HMQC-TOCSY, and NOESY two-dimensional NMR experiments.

Results and Discussion


Chemical Syntheses

Our synthetic approach to 16 α -methoxy estradiol-17 β (**6a**) involved reacting the trimethylsilyl enol ether of 3-benzyl estrone (**3**) with CH₃OF under optimized reaction conditions (Scheme 1). This reaction selectively yielded the 16 α -methoxy isomer with minimal or no formation of a 16 β -methoxy product as assessed by ¹H NMR by identifying the -OCH₃ shift at ca. 3.5 ppm. The electron-donating benzyl group on the A-ring affected the reactivity of the D-ring silyl enol ether of the estrogen. While ¹H NMR showed the desired methoxy ketone in 23% yield, column purification led to only a 10% overall yield for this reaction.



Scheme 1. Synthesis of 16 α -Methoxyestradiol-17 β .

Reacting CH_3OF with the silyl enol ether of 3-trifloxy estrone (**8**) yielded an isomeric mixture of 16α - and 16β -methoxy-3-OTf-estrone (**9a** and **9b**) in a 3:1 ratio, respectively (Scheme 2). The electron-withdrawing A-ring triflate increased the reactivity of the D-ring increasing the yield of methoxy products to 25-37% identified by ^1H NMR of the crude reaction mixture. The increased reactivity led to formation of the 16β -isomer requiring dual purification (silica gravity column chromatography; HPLC) to separate the 16α - from the 16β - isomer. This decreased the combined yield of isolated isomers to 10%.



Scheme 2. Synthesis of 16α -methoxyestradiol-17 α and 16β -methoxyestradiol-17 β .

Initial MeOF reactions involved direct addition of the enol ether substrate dissolved in CH_2Cl_2 to the $\text{CH}_3\text{OF} \cdot \text{ACN}$ at -40°C . This yielded a crude mixture of ca. 8 products detected by TLC with only minor formation of the desired product. A precipitate formed

upon substrate addition to the CH_3OF flask influencing the low yield of desired product. The substrate was determined to be insoluble in this composition of ACN and CH_2Cl_2 at -40°C causing precipitation. Conditions for substrate addition to $\text{CH}_3\text{OF}\cdot\text{ACN}$ were configured to maintain solubility of the enol ether while maintaining the reactivity of CH_3OF . The desired product yield was further increased by changing the substrate solvent to radical scavenging CHCl_3 .

Side product formation, presumably from reacting with HF formed during the generation of CH_3OF , was decreased by the addition of oven dried NaF to the $\text{CH}_3\text{OF}\cdot\text{ACN}$ immediately prior to transferring this solution to the CH_2Cl_2 dissolved substrate. Addition of NaF acts as a fluoride ion acceptor to decrease the acidity of HF through the formation of the HF_2^- ion which sequesters the ability of HF to react with the substrate.⁴

Reduction and deprotection of 16 α -methoxy-3-OTf-estrone (**9a**) with LiAlH_4 led to selective formation of the 16 α -methoxy estradiol-17 α (**6b**). This was unexpected as LiAlH_4 was used to reduce and deprotect 16 α -fluoro-3-OTf-estrone leading to the deprotected 17 β -OH and 17 α -OH estradiols in a 3:1 ratio.⁸ The 16 β -methoxy-3-OTf-estrone (**9b**) was reduced with LiAlH_4 to give the 16 β -methoxy estradiol-17 β (**6c**). This configuration was expected for the hydride can only attack from the α -face of the steroid as the 18 β -methyl and 16 β -methoxy are blocking the β -face. The combined reduction/deprotection step with LiAlH_4 was advantageous for past steroid syntheses, however, for this study it did not yield the desired 17 β -OH configuration with the 16 α -methoxy isomer (**9a**). Unexpected 17 α - and 17 β -OH ratios were also seen with the LiAlH_4 reduction/deprotection of 11 β -ethyl-16 β -fluoro-3-OTf-estrone. With the β -face being blocked by both the 11 β -ethyl, 16 β -fluoro, and 18 β -methyl substituents, the hydride attack from the unhindered α -face was expected, however, the attack from the shielded β -face prevailed by 1.6:1.¹⁶

Choice of reagent and reaction order determined which stereoisomer was preferentially formed. Desiring to selectively reduce **6a** to the 17 β -OH, a method using sodium borohydride (NaBH₄) in the presence of palladium chloride was applied as it is cited as selectively reducing 16 α -hydroxyestrone and 16 α -acetoxyestrone to the corresponding 17 β -estradiols.¹⁵ Direct application of this chemistry to 16 α -methoxy-3-OTf-estrone (**9a**) proved unacceptable. Reduction of the trifloxy protected estrone in the presence of palladium led to 16 α -methoxy-17 β -estrol formation. To preserve the hydroxy at the 3-position, deprotection of the triflate needed to precede ketone reduction. Deprotection with KOH/methanol at 60 °C successfully deprotected the triflate, however, base racemized the 16 α -methoxy favoring 16 β -methoxy formation 2:1. Stereoselective reduction in the presence of palladium chloride required prior deprotection in the absence of base. This was accomplished by protecting the 3-OH as a benzyl ether allowing rapid debenzylation by hydrogenolysis prior to NaBH₄ reduction in the presence of palladium.

2-D NMR Characterization

¹H NMR steroid peaks are difficult to assign due to severe overlap of resonances. To confirm the isomeric configurations of the methoxy estradiol compounds, two-dimensional (2-D) correlated NMR techniques were instituted. COSY-like (H, H) methods of analysis generally fail for steroids as the ¹H dispersion is poor. Good ¹³C dispersion seen with steroids makes identification techniques like HMQC-TOCSY (heteronuclear multiple quantum coherence - total correlation spectroscopy) useful as steroids have carbons with attached protons on the B, C, and D rings. TOCSY provides information in a two-dimensional format indicating the correlations between protons belonging to a common spin system.¹ HMQC experiments correlating ¹H-¹³C one-bond coupling combined with the extended coupling identified by HMQC-TOCSY allows assignment of the steroid skeleton. The HMQC and HMQC-TOCSY assignments for compounds **6a**, **6b**, and **6c** are listed in Tables 2, 3, and 4 respectively.

Table 2: HMQC and HMQC-TOCSY assignments for 16 α -Methoxy Estradiol-17 β (**6a**).

16 α -OMe-E2-17 β Assignment No. ^a	HMQC ¹ H Chemical Shift (ppm)	HMQC ¹³ C Chemical Shift (ppm)	HMQC-TOCSY Chemical Shift: ¹³ C to ¹ H Shift of HMQC (ppm)
17	3.64	88.2	---
16	3.70	88.0	30.9
15	1.72	30.9	48.4; 88.0
14	1.50	48.4	30.9; 38.8
12	1.35; 1.91	37.0	26.5
11	1.47; 2.29	26.5	37.0
9	2.22	44.2	26.5; 38.8
8	1.43	38.8	27.6; 44.2; 48.4
7	1.36; 1.85	27.6	29.9; 38.8
6	2.82	29.9	27.6
18	0.81	13.0	---
OMe	3.39	57.9	---

^aCorresponds to the steroidal numbering system.Table 3: HMQC and HMQC-TOCSY assignments for 16 α -Methoxy Estradiol-17 α (**6b**).

16 α -OMe-E2-17 α Assignment No. ^a	HMQC ¹ H Chemical Shift (ppm)	HMQC ¹³ C Chemical Shift (ppm)	HMQC-TOCSY Chemical Shift: ¹³ C to ¹ H Shift of HMQC (ppm)
17	3.76	77.3	81.5
16	4.00	81.5	31.6; 77.3
15	1.72	31.6	46.6; 81.5
14	1.88	46.6	31.6; 39.0
12	1.63; 1.96	31.6	26.1
11	1.52; 2.30	26.1	31.6; 44.0
9	2.24	44.0	26.1; 39.0
8	1.35	39.0	28.3; 44.0; 46.6
7	1.40; 1.84	28.3	30.0; 39.0*
6	2.82	30.0	28.3
18	0.71	17.0	---
OMe	3.40	58.0	---

^aCorresponds to the steroidal numbering system.*Not seen for ¹H = 1.84.

Table 4: HMQC and HMQC-TOCSY assignments for 16 β -Methoxy Estradiol-17 β (**6c**).

16 β -OMe-E2-17 β Assignment No. ^a	HMQC ¹ H Chemical Shift (ppm)	HMQC ¹³ C Chemical Shift (ppm)	HMQC-TOCSY Chemical Shift: ¹³ C to ¹ H Shift of HMQC (ppm)
17	3.49	79.0	81.1
16	3.74	81.1	32.1; 79.0
15	1.73	32.1	46.5; 81.1
14	1.80	46.5	32.1; 38.2
12	1.62; 1.96	31.9	26.1
11	1.50; 2.35	26.1	31.9; 44.1
9	2.25	44.1	26.1; 38.2
8	1.35	38.2	27.4; 44.1; 46.5
7	1.42; 1.87	27.4	30.6; 38.2*
6	2.82	30.6	27.4
18	0.79	**	---
OMe	3.37	57.6	---

^aCorresponds to the steroidal numbering system.*Not seen for ¹H = 1.87.

**Due to an impurity, the assignment was indistinguishable from 14.1 or 11.7 ppm.

Confirmation of the stereochemistry at the 16- and 17-position was obtained by a NOESY (nuclear Overhauser effect spectroscopy) experiment which looked at dipole-dipole interactions through space (Table 5). The combination of these techniques was essential for assignment of each isomer's D-ring stereochemistry.

Table 5. NOESY assignments represented as the average relative volume to confirm the stereochemistry of 16-Methoxy Estradiol isomers.

Interacting H Pairs	NOE	NOE	NOE
	16 α -OMe-E2-17 β (6a)	16 α -OMe-E2-17 α (6b)	16 β -OMe-E2-17 β (6c)
H ₁₇ - H ₁₆	0.271	0.825	0.271
H ₁₇ - H ₁₄	1.852	0.058	---
H ₁₇ - OMe	0.376	0.148	**
H ₁₆ - OMe	1.184	0.828	0.440
18-CH ₃ - H ₁₆	1.160	0.808	0.063
18-CH ₃ - H ₁₇	---	0.833	0.112

---A missing value represents that an NOE was not seen for this interaction.

**Represents an obscured interaction by either a cross-peak or an artifact.

Relative Binding Affinities

The relative binding affinities (RBA) of the 16-methoxy estradiols for the estrogen receptor were determined by a competitive radiometric binding assay using lamb uterine estrogen receptor.⁷ The highest RBA for the methoxy estradiol series was 2.3 for **6c** while the RBA for **6a** and **6b** was 1.5 and 0.5, respectively. The isomers of 16-methoxy estradiol all displayed low binding affinity for the ER compared to estradiol and 16-halogenated estradiols (Table 1). Halogens substituted at the 16 α -position retain binding affinity suggesting that the receptor-ligand interaction is maintained with electron-withdrawing groups. The electron-donating methoxy may have disrupted this interaction leading to the unfavorable ligand-receptor association.

The size of the methoxy substituent may be an additional contributor to the low RBA. The space occupied by the methoxy is greater than that of iodine, the largest substituted halogen (Table 6). Comparing the relative binding affinities for the halogens shows a decrease in RBA between chlorine and iodine. If size is a problem, it is hypothesized that the RBA decreases as the size of a substituted group at the 16-position increases beyond 2 Å.

Table 6. Correlation of volume occupied at the 16-position of estradiol to the estrogen receptor's RBA.

Substitution at the 16 α -Position	Size of Group (Å)	RBA for the ER
F	1.38	76
Br	1.94	100
Cl	1.76	129
I	2.08	93
OMe	2.69	1.5

Conclusion

Two different synthetic routes were required to obtain three isolated isomers of 16-methoxy estradiol. Methyl hypofluorite incorporated the methoxy at the 16-position of the steroid skeleton allowing evaluation of this ligand's ability to bind the ER. This study transferred the chemistry of CH_3OF from simple molecules to those of a more complex nature. The chemistry of CH_3OF was useful for the synthesis of methoxy substituted estrogens and will be applied to the compounding of a future steroidal target compound. Methyl hypofluorite will introduce a methoxy substitution at the 15-position of estradiol. It is unknown how a substitution at this position will affect binding affinity to the estrogen receptor.

Two-dimensional correlative NMR techniques were instrumental in the characterization of these isomers. The stereochemistry of the isomers was confirmed by identification of dipole-dipole interactions with NOESY. HMQC and HMQC-TOCSY provided a solid means of mapping the steroid structure through analysis of ^1H - ^{13}C coupling. These NMR techniques would be advantageous for further steroid characterization.

This series of compounds was investigated in the pursuit of new estrogen receptor breast cancer imaging agents. The tolerance of the estrogen receptor for substituted estrogen derivatives was further mapped. A methoxy substitution at the 16-position of estradiol decreased the binding to the estrogen receptor due to steric and/or electronic effects. The low binding-affinities of the methoxy estradiols predict these compounds to be poor visualizers of the estrogen receptor, therefore, unsuitable as estrogen receptor imaging agents. Compounds with low affinity for the receptor will not selectively accumulate at the site of interest. Binding to the receptor at the target site is an important requirement for radiopharmaceuticals. Non-selective distribution would lead to an undesired radiation dose at non-target sites. These compounds will not be radiolabeled for further evaluation due to their unfavorable binding affinities. With a better understanding of the requirements for an

agent to bind the estrogen receptor, the engineering of superior breast cancer imaging agents can advance.

Comments

Much of this pre-doctoral research project has focused on the optimization, synthesis, characterization and evaluation of the three isomers of 16-methoxy estradiol. This took a high level of effort to achieve these target compounds that had not been previously prepared. Although these compounds turned out to be not useful, the information obtained will benefit several areas of chemistry and medicine.

Experimental Section

General. All commercial reagents were used as received from the suppliers unless otherwise noted. HPLC solvents were Optima grade. Fluorine (20% in Ne) was purchased from Acetylene Gas (St. Louis, MO). Due to the strong oxidizing and corrosive nature of fluorine, appropriate laboratory equipment should be instituted.¹⁸ 2,6-Lutidine was distilled from barium oxide and stored over molecular sieves. Methylene chloride (CH_2Cl_2) and triethylamine (TEA) were distilled from calcium hydride (CaH_2). Column chromatography was performed using silica gel (60 Å, 230-400 mesh) or basic alumina (40 µm). TLC was performed on UV active 250 µm silica plates visualized with phosphomolybdic acid or potassium permanganate. Melting points are uncorrected. ^1H and ^{19}F NMR spectra were obtained on a Varian Associates, Inc., Gemini spectrometer at 300 (or 500 MHz) and 282 MHz, respectively. Chemical shifts for ^1H and ^{13}C are referenced to internal tetramethylsilane (δ scale). ^{19}F chemical shifts are reported in ppm upfield from internal CFCl_3 (ϕ scale). Microanalyses were performed by Galbraith Laboratories Inc. 3-[[[(Trifluoromethyl)sulfonyl]oxy]estra-1,3,5(10)-trien-17-one (**7**) was prepared according to the literature.⁸ General work-up of organic solutions included drying over MgSO_4 , filtering, and removing solvent under reduced pressure.

3-(Benzyloxy)estra-1,3,5(10)-trien-17-one (2). A solution of **1** (1.2 g, 4.44 mmol) and BnBr (1.06 ml, 8.88 mmol) were added to a mixture of 50 ml CHCl_3 , 25 ml MeOH, and K_2CO_3 (1.23 g, 8.88 mmol) that had refluxed under N_2 for 15 min. The reaction was refluxed for 21 hr, cooled to rt, filtered, and filtrate concentrated under reduced pressure. Residue was dissolved in CH_2Cl_2 , washed with 1x100 ml 1 N HCl, followed by general work-up. Recrystallization from MeOH yielded **2** as a white solid (0.978 g, 61%). mp 126-128 °C. ^1H NMR (CDCl_3): δ 0.91 (s, 3H, 18- CH_3), 1.30-2.60 (m, 13H), 2.90 (m, 2H), 5.04 (s, 2H, PhCH_2OAr), 6.74 (d, $J = 2.7$, 1H), 6.79 (dd, $J = 8.6, 2.7$, 1H), 7.21 (d, $J = 8.7$, 1H), 7.32-7.45 (m, 5H). HRMS calcd for $\text{C}_{25}\text{H}_{28}\text{O}_2$ (M^+) 360.2089, found 360.2081.

17-(Trimethylsilyl)oxy-3-(benzyloxy)estra-1,3,5(10),16-tetraene (3). To a solution of benzy ketone **2** (0.770 g, 2.14 mmol) in 15 mL CH_2Cl_2 under N_2 was added Et_3N (1.55 mL, 11.1 mmol, 5.2 eq). The solution was stirred for 20 m prior to addition of TMSOTf (1.24 mL, 8.88 mmol, 4 eq) followed by 30 m of stirring. Reaction was deposited directly onto a basic alumina column and eluted with 25% CH_2Cl_2 , 75% hexane, 1% Et_3N , followed by general work-up. Product coeluted with unreacted starting material. Purification by basic alumina flash column chromatography (20% EtOAc, 80% hexane) yielded **3** as a white solid (0.92g, 100%). mp 105-107 °C. ^1H NMR (CDCl_3): δ 0.22 (s, 3H); 0.86 (s, 3H); 1.39-2.4 (m, 11H); 2.85-2.91 (m, 2H); 4.52 (m, 1H); 5.03 (s, 2H, PhCH_2OAr); 6.73 (d, $J = 2.7$, 1H); 6.78 (dd, $J = 8.4, 2.7$, 1H); 7.19 (d, $J = 8.7$, 1H); 7.31-7.45 (m, 5H). HRMS calcd for $\text{C}_{28}\text{H}_{36}\text{O}_2\text{Si}$ (M^+) 432.2485, found 432.2492.

17-(Trimethylsilyl)oxy-3-[[trifluoromethylsulfonyl]oxy]estra-1,3,5(10),16-tetraene (8). Procedure A (adapted from Cazeau²). To a flask containing trifyl ketone **7** under N_2 (0.514 g, 1.28 mmol), Et_3N (221 μL , 1.59 mmol, 1.24

eq) was added followed by TMSCl (201 μ L, 1.59 mmol, 1.24 eq). The resulting white slurry was stirred while NaI (0.238 g, 1.59 mmol, 1.24 eq) in anhydrous ACN (1.6 mL) was added dropwise. Cold hexane and ice water were added after the solution was stirred at rt for ca. 66 h. After decantation, the aqueous layer was washed with hexane and the combined organic extracts were washed thrice with cold saturated sodium bicarbonate followed by general work-up. Purification by silica flash column chromatography (10% EtOAc, 90% hexane) yielded **8** as a white solid (0.304 g, 50%).

Procedure B. To a solution of triflyl ketone **7** (2.53 g, 6.29 mmol) in 40 mL CH_2Cl_2 under N_2 was added Et_3N (1.76 mL, 12.58 mmol, 2 eq). After the solution was stirred for 20 m and cooled to 0 $^\circ\text{C}$, TMSOTf (2.44 mL, 12.58 mmol, 2 eq) was added. Cold bath was removed to allow the reaction to proceed at rt. Reaction was monitored by TLC (23% EtOAc, 77% hexane) and additional Et_3N (2.0 mL) and TMSOTf (1.5 mL) were added to maximize the yield of the enoxy silane over a reaction time of 3 h. Reaction mixture was deposited directly on a basic alumina plug and eluted with 25% CH_2Cl_2 , 75% hexane, 1% Et_3N . Solvent removed under reduced pressure to afford the desired enoxy silane (2.70 g, 90%). mp 84-88 $^\circ\text{C}$. ^1H NMR (CDCl_3): δ 0.21 (s, 9H); 0.88 (s, 3H); 0.97-2.10 (m, 11H); 2.35-2.40 (m, 2H); 4.55 (m, 1H); 6.72-6.82 (m, 3H). Anal. Calcd for $\text{C}_{22}\text{H}_{29}\text{O}_4\text{F}_3\text{SSi}$: C, 55.68; H, 6.16. Found: C, 56.12; H, 6.34.

General Procedure For Methyl Hypofluorite (CH_3OF) Reactions. To a N_2 swept flask were added 48 mL anhydrous ACN and 2 mL anhydrous MeOH and cooled to -40 $^\circ\text{C}$ in a dry ice/acetonitrile bath. Nitrogen flow was removed and F_2 (20% in Ne) was bubbled through the solution for 35 m. An aliquot (0.5 mL) was removed and added to a flask containing 25 mL H_2O and KF. Titration of the solution with $\text{Na}_2\text{S}_2\text{O}_4$ (equivalence point color change: yellow to colorless) determined the concentration of CH_3OF . The desired substrate was dissolved in CHCl_3 (10 mL) and cooled to 0 $^\circ\text{C}$. NaF (30 mg) was added to the solution of CH_3OF and swirled for 30 sec before the CH_3OF was quickly

poured into the substrate flask. The reaction was stirred at 0 °C for 5 m followed by warming to rt over 40 m. Reaction was quenched by addition to saturated NaHCO₃ (250 mL) with stirring. Separation of the aqueous phase was following by washing the aqueous extract thrice with CHCl₃. The combined organic extracts were washed thrice with brine followed by general work-up.

16 α -Methoxy-3-(benzyloxy)estra-1,3,5(10)-triene-17-one (4). The general procedure was followed to generate 6.90 mmol CH₃OF (0.139 M) to react with **3** (570 mg, 1.32 mmol). Purification by gravity silica column chromatography (30% hexane; 70% CH₂Cl₂) afforded **4** as a white solid (52 mg, 10%). ¹H NMR (CDCl₃): δ 0.88 (s, 3H, 18-CH₃); 1.26-2.10 (m, 11H); 2.85-2.95 (m, 2H); 3.52 (s, 3H, -OCH₃); 3.97 (d, J = 7.5, 1H); 5.03 (s, 2H); 6.70-6.81 (m, 2H); 7.19 (d, J = 8.7, 1H), 7.27-7.44 (m, 5H).

16 α -Methoxy-3-[[trifluoromethyl)sulfonyl]oxy]estra-1,3,5(10)-triene-17-one (9a). The above procedure was followed to generate 5.11 mmol CH₃OF (0.105 M) to react with **8** (330 mg, 0.695 mmol). Purification by silica flash column chromatography (15% EtOAc, 85% hexane) followed by semi-preparative normal phase HPLC (6% 1:19 isopropanol:CH₂Cl₂, 94% hexane) afforded **9a** as a white solid (36 mg, 12%). ¹H NMR (CDCl₃): δ 0.96 (s, 3H, 18-CH₃); 1.25-2.45 (m, 11H); 2.90-2.98 (m, 2H); 3.53 (s, 3H, -OCH₃); 3.98 (d, J = 7.2 Hz, 1H, 16-H); 6.98-7.06 (m, 2H); 7.34 (d, J = 8.5, 1H). HRMS calculated for C₂₀H₂₃O₅F₃S (M+H)⁺ 433.1296, found 433.1300.

16 β -Methoxy-3-[[trifluoromethyl)sulfonyl]oxy]estra-1,3,5(10)-triene-17-one (9b). The above procedure was followed to generate 5.11 mmol CH₃OF (0.105 M) to react with **8** (330 mg, 0.695 mmol). Purification by silica flash column chromatography (15% EtOAc, 85% hexane) followed by semi-preparative normal phase HPLC (6% 1:19 isopropanol:CH₂Cl₂, 94% hexane) afforded **9b** as a white solid (12 mg, 4%). ¹H NMR

(CDCl₃): δ 1.00 (s, 3H, 18-CH₃); 1.22-2.58 (m, 11H); 2.93-2.98 (m, 2H); 3.54 (s, 3H, -OCH₃); 3.67 (t, J = 8.2 Hz, 1H, 16-H); 7.00-7.05 (m, 2H); 7.34 (d, J = 8.2, 1H).

HRMS calculated for C₂₀H₂₃O₅F₃S (M⁺) 432.1218, found 432.1208.


16 α -Methoxy-estra-1,3,5(10)-triene-3-ol-17-one (5). Benzyl ester **4** (17.3 mg, 0.045 mmol) was dissolved in 1 ml EtOAc and a suspension of 4 mg PdCl₂(CH₃CH₂)₂ and 8 μ l EtOH was added. The reaction mixture was stirred under H₂ for 25 min, progressing through a color change from yellow to clear and colorless. The reaction mixture was diluted with CH₂Cl₂, filtered, and concentrated under reduced pressure. Crude reaction was redissolved in 1 ml EtOAc and passed through a silica plug eluted with 1:1 EtOAc:hexane. Procedure was repeated twice with **4**. Pooled reactions were not further purified. ¹H NMR showed complete deprotection. ¹H NMR (CDCl₃): δ 0.94 (s, 3H, 18-CH₃); 1.95-2.40 (m, 11H); 2.85 (m, 2H); 3.52 (s, 3H, -OCH₃); 3.98 (d, J = 7.4, 1H); 5.05 (b, < 1H, OH); 6.57-6.65 (m, 2H); 7.13 (d, J = 8.1, 1H).

16 α -Methoxy-estra-1,3,5(10)-triene-3,17 β -diol (6a). To a solution of **5** (13 mg, 0.0433 mmol) in 2 ml anhydrous MeOH was added PdCl₂ (15 mg, 0.087 mmol). While stirring under N₂, the reaction was cooled to 0 °C and NaBH₄ was added (9.8 mg, 0.260 mmol) and the reaction was stirred for 4 h. Reaction was filtered into 8 ml 5% HOAc followed by the addition of EtOAc and 1 M NaHCO₃. Following separation of layers, aqueous fraction was washed 3x15 ml EtOAc. Combined organic fractions were washed 3x30 ml H₂O followed by general work-up. Procedure was repeated twice with **5** and the crude reactions were pooled prior to semi-preparative silica HPLC purification (30% 1:19 isopropanol:CH₂Cl₂, 70% hexane) which yielded the methoxy estradiol **6a** as a white solid (8.1 mg, 20% from **4**). ¹H NMR (CDCl₃): δ 0.81 (s, 3H, 18-CH₃); 1.30-2.35 (m, 12H); 2.80-2.85 (m, 2H); 3.39 (s, 3H, -OCH₃); 3.64 (d, J = 5.4, 1H, 17-H);

3.68-3.74 (m, 1H, 16-H); 4.50-4.80 (b, < 1H, OH); 6.58-6.68 (m, 2H); 7.17 (d, J = 8.1, 1H).

16-Methoxy-estra-1,3,5(10)-triene-3,17-diol (6b, 6c). Methoxy triflate estrone (0.0694 mmol, 30 mg **9a** or 0.0176 mmol, 7.6 mg **9b**) was dissolved in freshly distilled Et₂O (0.013 mmol/mL), stirred under N₂, and cooled to -78 °C in a dry ice/isopropanol bath. A 1.0 M LiAlH₄ solution in Et₂O (0.350 mmol, 350 µL to **9a** or 0.087 mmol, 87 µL to **9b**) was added dropwise over ca. 2 m. The pale yellow reaction was stirred at -78 °C for 25 m after which it was removed from the cold bath and allowed to warm to rt over 25 m giving a cloudy white appearance. Addition of 6 N HCl (7.8 mmol, 1.3 mL for **9a** or 1.044 mmol, 0.174 mL for **9b**) quenched the reaction. The organic phase was removed and the remaining aqueous phase extracted with 1x3 mL Et₂O and 2x3 mL 1:1 CH₂Cl₂:hexane. Each organic extract was passed through a MgSO₄ plug (2 g) and a 0.22 µ filter. Solvent was removed under reduced pressure. Purification by semi-preparative normal phase HPLC (40% 1:19 isopropanol:CH₂Cl₂, 60% hexane) yielded **6b** (0.022 mmol, 6.6 mg, 31%) or **6c** (0.0175 mmol, 5.3 mg, 83%) as a white solid. **6b** ¹H NMR (CDCl₃): δ 0.71 (s, 3H, 18-CH₃); 1.20-2.40 (m, 12H); 2.78-2.85 (m, 2H); 3.40 (s, 3H, -OCH₃); 3.76 (d, J = 5.1, 1H, 17-H); 3.99-4.05 (m, 1H, 16-H); 4.68-4.80 (b, < 1H, OH); 6.55-6.68 (m, 2H); 7.16 (d, J = 8.4, 1H). HRMS calculated for C₁₉H₂₆O₃ (M⁺) 302.1882, found 302.1883. **6c** ¹H NMR (CDCl₃): δ 0.79 (s, 3H, 18-CH₃); 0.95-2.40 (m, 12H); 2.80-2.85 (m, 2H); 3.37 (s, 3H, -OCH₃); 3.49 (d, J = 7.8, 1H, 17-H); 3.73-3.78 (m, 1H, 16-H); 6.55-6.65 (m, 2H); 7.16 (d, J = 8.7, 1H). HRMS calculated for C₁₉H₂₆O₃ (M⁺) 302.1882, found 302.1881.

Time Line for Statement of Work



*Three compounds have been synthesized to date.

List of Abbreviations

ACN	acetonitrile
BnBr	α -bromotoluene
CaH ₂	calcium hydride
CDCl ₃	deuterated chloroform: NMR solvent
CFCl ₃	fluorotrichloromethane
CH ₂ Cl ₂	methylene chloride
CH ₃ OF	methyl hypofluorite
CH ₃ OF•ACN	methyl hypofluorite/acetonitrile complex
CHCl ₃	chloroform
COSY	correlation spectroscopy
ER	estrogen receptor
ER+	estrogen receptor positive
ES	estradiol: the natural ER ligand
Et ₂ O	diethyl ether
Et ₃ N	triethyl amine
EtOAc	ethyl acetate
EtOH	ethanol
F ₂	fluorine (gas)
FES	[¹⁸ F]-16 α -fluoroestradiol-17 β
H ₂	hydrogen (gas)
HCl	hydrochloric acid
HF	hydrofluoric acid
HMQC	heteronuclear multiple quantum coherence
HOAc	acetic acid
HPLC	high-performance liquid chromatography
HRMS	high-resolution mass spectrum

K_2CO_3	potassium carbonate
KF	potassium fluoride
$LiAlH_4$	lithium aluminum fluoride
MeOH	methanol
$MgSO_4$	magnesium sulfate
N_2	nitrogen (gas)
$Na_2S_2O_4$	sodium thiosulfate
$NaBH_4$	sodium borohydride
NaF	sodium fluoride
$NaHCO_3$	sodium bicarbonate
NaI	sodium iodide
NMR	nuclear magnetic resonance
NOESY	nuclear Overhauser effect spectroscopy
$PdCl_2$	palladium chloride
$PdCl_2(CH_3CH)_2$	palladium chloride diacetoneitrile
PET	positron emission tomography
RBA	relative binding affinity
rt	room temperature
TEA	triethyl amine
Tf	trifluoromethanesulfonyl (triflyl)
TLC	thin-layer chromatography
TMSCl	chlorotrimethyl silane
TMSOTf	trimethyl silyl triflate
TOCSY	total correlation spectroscopy
UV	ultraviolet

References

1. Braunschweiler, L.; Ernst, R. R. *J. Mag. Res.* **1983**, *53*, 521-528.
2. Cazeau, P.; Duboudin, F.; Moulines, F.; Babot, O.; Dunogues, J. *Tetrahedron* **1987**, *43*, 2075-2088.
3. Corey, E. J.; Knapp, S. *Tetrahedron Letters* **1976**, *51*, 4687-4690.
4. Cotton, F. A.; Wilkinson, G. *Advanced Inorganic Chemistry*, 5th ed.; John Wiley & Sons: New York, 1988.
5. Dehdashti, F.; Mortimer, J. E.; Siegel, B. A.; Griffeth, L. K.; Dobkin, J. A.; Bonasera, T. A.; Fusselman, M. J.; Detert, D. D.; Cutler, P. D.; Katzenellenbogen, J. A.; Welch, M. J. *Journal of Nuclear Medicine* **1995**, *36*, 1766-1774.
6. Katzenellenbogen, J. A. Estrogen and Progestin Radiopharmaceuticals for Imaging Breast Cancer. In *Estrogens, progestins, and their antagonists*; Pavlik, E. J. Ed.; Birkhäuser: Boston, 1996; Vol. 1; pp. 197-242.
7. Katzenellenbogen, J. A.; Jr., H. J. J.; Myers, H. N. *Biochemistry* **1973**, *12*, 4085-4092.
8. Kieseewetter, D. O.; Katzenellenbogen, J. A.; Kilbourn, M. R.; Welch, M. J. *Journal of Organic Chemistry* **1984**, *49*, 4900-4905.
9. Kol, M.; Rozen, S.; Appelman, E. *Journal of the American Chemical Society* **1991**, *113*, 2648-2651.
10. Långström, B. R. *Acta Chemica Scandinavia* **1990**, *147*, S374.
11. McCarthy, T. J.; Bonasera, T. A.; Welch, M. J.; Rozen, S. *J. Chem. Soc., Chemical Communications* **1993**, 561-562.
12. McGuire, A. H.; Dehdashti, F.; Siegel, B. A.; Lyss, A. P.; Brodack, J. W.; Mathias, C. J.; Mintun, M. A.; Katzenellenbogen, J. A.; Welch, M. J. *Journal of Nuclear Medicine* **1991**, *32*, 1526-1531.
13. Mintun, M. A.; Welch, M. J.; Siegel, B. A.; Mathias, C. J.; Brodack, J. W.; McGuire, A. H.; Katzenellenbogen, J. A. *Radiology* **1988**, *169*, 45-48.

14. Moriarty, R. M.; Prakash, O.; M.P.Duncan; Vaid, R. K. *J. Org. Chem* **1987**, *52*, 150-153.
15. Numazawa, M.; Nagaoka, M.; Tsuji, M. *J. Chem. Soc. Perkin Trans.* **1983**, *1*, 121-125.
16. Pomper, M. G.; VanBrocklin, H. F.; Thieme, A. M.; Thomas, R. D.; Kieseewetter, D. O.; Carlson, K. E.; Mathias, C. J.; Welch, M. J.; Katzenellenbogen, J. A. *Journal of Medicinal Chemistry* **1990**, *33*, 3143-3155.
17. Rozen, S.; Mishani, E.; Kol, M. *Journal of the American Chemical Society* **1992**, *114*, 7643-7645.
18. Vypel, H. *Chimia* **1985**, *39*, 305.